Is CCCC a good stock to buy? C4 Therapeutics, Inc. (NASDAQ:CCCC) was in 20 hedge funds' portfolios at the end of March. The all time high for this statistic is 22. CCCC investors should pay attention ...
From a technical perspective, C4 Therapeutics, Inc. (CCCC) is looking like an interesting pick, as it just reached a key level of support. CCCC's 50-day simple moving average crossed above its 200-day ...
The average one-year price target for C4 Therapeutics (NasdaqGS:CCCC) has been revised to $11.51 / share. This is an increase of 14.49% from the prior estimate of $10.05 dated February 1, 2026. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results